Table 1 Baseline patient characteristics (n = 50)
Parameter | N (%) |
|---|---|
Sex, male | 29 (58) |
Median age at diagnosis, yrs. (range) | 56 (41–68) |
Diagnosis | |
IgG | 20 (40 %) |
IgA | 11 (22 %) |
IgD | 2 (4 %) |
Light chain | 16 (32 %) |
Plasma cell leukemia | 1 (2 %) |
Durie and Salmon stage | |
IA | 2 (4) |
IIA | 17 (34) |
IIIA | 29 (58) |
IIIB | 1 (2) |
Na (a) | 1 (2) |
ISS stage | |
1 | 26 (52) |
2 | 17 (34) |
3 | 5 (10) |
Na (a) | 1 (2) |
Cytogenetic analysis [21] | |
High risk | 6 (12 %) |
Intermediate risk | 8 (16 %) |
Standard risk | 35 (70 %) |
Na (a) | 1 (2 %) |
Induction treatment | |
VAD (b) | 23 (46) |
Novel agents (c) | 27 (54) |
Up-front tandem ASCT (d) | 50 (100) |